Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
Dec 8, 2016 → Apr 24, 2017
NCT ID
NCT02954354About Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir is a phase 3 stage product being developed by Shionogi for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02954354. Target conditions include Influenza.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02949011 | Phase 3 | Completed |
| NCT02954354 | Phase 3 | Completed |
Competing Products
20 competing products in Influenza